ATLASATLAS fair value
₹884.40
Above fair value · 48% premium
Range: ₹796–₹973Fair valuePrice
Concord Biotech (CONCORDBIO.NSE)
Concord Biotech share price today, ATLAS forecast and fair value
Healthcare · Biotechnology · National Stock Exchange of India · India
₹1,311▲ +6.66%
Prices as of Oct 26, 2026 · INR
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Concord Biotech in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Concord Biotech
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Concord Biotech's fair value at about ₹884.40 per share (reasonable range: ₹795.96 to ₹972.84). At ₹1,311, the stock trades 48% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Concord Biotech a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹1,220 and ₹1,406; in 9 out of 10, between ₹1,075 and ₹1,595. Estimated annual volatility is 41%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₹135B
- Market cap (USD)
- $1.4B
- P/E ratio
- 42.4
- Dividend yield
- 2.30%
- 52-week high
- ₹1,615
- 52-week low
- ₹987.00
- Revenue (12 months)
- ₹11.1B
- Operating margin
- 25.0%
- Net margin
- 24.8%
- Beta
- 0.37
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Concord Biotech sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks CONCORDBIO.NSE has traded between ₹987.00 and ₹1,615. Today it is 18.8% below that high and 33% above its low.
On the business: net margin is 24.8%; it trades at 42.4 times earnings.
Its beta is 0.37: it tends to move less than the market.
About the company
Concord Biotech Ltd. is an innovative biopharmaceutical company engaged in the research, development, and manufacture of biopharmaceutical ingredients and products.
Want to see everything about Concord Biotech?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Concord Biotech (CONCORDBIO.NSE) fair value?
About ₹884.40 per share according to ATLAS (reasonable range: ₹795.96 to ₹972.84). With the stock at ₹1,311, it is 48% above it.
What is the chance CONCORDBIO.NSE goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, CONCORDBIO.NSE ends the month between ₹1,220 and ₹1,406.
How big is Concord Biotech and what is its P/E ratio?
Concord Biotech's market capitalization is ₹135B. Its price-to-earnings (P/E) ratio is 42.4: you pay ₹42.4 for each ₹1.00 of yearly earnings.
Does Concord Biotech pay a dividend?
Yes. CONCORDBIO.NSE's current dividend yield is 2.30% at today's price (₹1,311).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer